Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

NCT02383927 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Cancer
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
HRAS Mutant Tumor
Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Interventions

DRUG: Tipifarnib

Sponsor

Kura Oncology, Inc.